370 related articles for article (PubMed ID: 31118051)
21. Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis.
Marinello PC; Panis C; Silva TNX; Binato R; Abdelhay E; Rodrigues JA; L Mencalha A; Lopes NMD; Borges FH; Luiz RC; Cecchini R; Cecchini AL
Pathol Res Pract; 2020 Oct; 216(10):153135. PubMed ID: 32853957
[TBL] [Abstract][Full Text] [Related]
22. Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells.
Genna A; Lapetina S; Lukic N; Twafra S; Meirson T; Sharma VP; Condeelis JS; Gil-Henn H
J Cell Biol; 2018 Jan; 217(1):375-395. PubMed ID: 29133485
[TBL] [Abstract][Full Text] [Related]
23. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
[TBL] [Abstract][Full Text] [Related]
24. Amorphophalli Rhizoma inhibits breast cancer growth, proliferation, migration, and invasion via the PI3K/AKT pathway.
Li H; Chen M; Yang Z; Xu C; Yu Q; Song J; Wang M; Gao X
J Ethnopharmacol; 2022 Mar; 286():114926. PubMed ID: 34929308
[TBL] [Abstract][Full Text] [Related]
25. ∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER
Liu Y; Nekulova M; Nenutil R; Horakova I; Appleyard MV; Murray K; Holcakova J; Galoczova M; Quinlan P; Jordan LB; Purdie CA; Vojtesek B; Thompson AM; Coates PJ
J Pathol Clin Res; 2020 Jan; 6(1):83-93. PubMed ID: 31591823
[TBL] [Abstract][Full Text] [Related]
26. NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.
Wang Y; Yan L; Zhang L; Xu H; Chen T; Li Y; Wang H; Chen S; Wang W; Chen C; Yang Q
Int J Oncol; 2018 Sep; 53(3):1043-1054. PubMed ID: 30015868
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of MIIP regulates human breast cancer proliferation, invasion and migration by mediated by IGFBP2.
Du Y; Wang P
Pathol Res Pract; 2019 Jul; 215(7):152440. PubMed ID: 31078343
[TBL] [Abstract][Full Text] [Related]
29. Lnc RNA SNHG20 participated in proliferation, invasion, and migration of breast cancer cells via miR-495.
Guan YX; Zhang MZ; Chen XZ; Zhang Q; Liu SZ; Zhang YL
J Cell Biochem; 2018 Nov; 119(10):7971-7981. PubMed ID: 29236315
[TBL] [Abstract][Full Text] [Related]
30. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
[TBL] [Abstract][Full Text] [Related]
31. WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling.
Teng Y; Pi W; Wang Y; Cowell JK
Oncogene; 2016 Sep; 35(35):4633-40. PubMed ID: 26804171
[TBL] [Abstract][Full Text] [Related]
32. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
33. Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47.
Tan W; Tang H; Jiang X; Ye F; Huang L; Shi D; Li L; Huang X; Li L; Xie X; Xie X
J Cell Mol Med; 2019 Sep; 23(9):5994-6004. PubMed ID: 31273952
[TBL] [Abstract][Full Text] [Related]
34. Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.
Aceto N; Duss S; MacDonald G; Meyer DS; Roloff TC; Hynes NE; Bentires-Alj M
Breast Cancer Res; 2012 Oct; 14(5):R131. PubMed ID: 23062209
[TBL] [Abstract][Full Text] [Related]
35. Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells.
Schmucker H; Blanding WM; Mook JM; Wade JF; Park JP; Kwist K; Shah H; Booth BW
Cell Oncol (Dordr); 2018 Apr; 41(2):159-168. PubMed ID: 29181633
[TBL] [Abstract][Full Text] [Related]
36. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
37. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT.
Hu C; Li M; Guo T; Wang S; Huang W; Yang K; Liao Z; Wang J; Zhang F; Wang H
Phytomedicine; 2019 May; 58():152740. PubMed ID: 31005718
[TBL] [Abstract][Full Text] [Related]
38. Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.
Kumari K; Keshari S; Sengupta D; Sabat SC; Mishra SK
BMC Cancer; 2017 Dec; 17(1):858. PubMed ID: 29246124
[TBL] [Abstract][Full Text] [Related]
39. Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer.
Wu X; Li Y; Wang J; Wen X; Marcus MT; Daniels G; Zhang DY; Ye F; Wang LH; Du X; Adams S; Singh B; Zavadil J; Lee P; Monaco ME
PLoS One; 2013; 8(10):e77060. PubMed ID: 24155918
[TBL] [Abstract][Full Text] [Related]
40. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
